Cannabis users hospitalized for hyperemesis had dangerously low phosphate levels that resolved on their own within hours | Research

The takeaway

Six men hospitalized with cannabinoid hyperemesis syndrome had significant hypophosphatemia (dangerously low phosphate), with levels normalizing spontaneously within hours in some cases, possibly from hyperventilation-driven redistribution.

Read this if you want to know about an under-recognized complication of cannabinoid hyperemesis syndrome.

Phosphate levels dropped to <1.0 mg/dL (normal: 2.5-4.5) in CHS patients

What the researchers found

Between 2011 and 2014, six men treated for cannabinoid hyperemesis syndrome (CHS) at a VA Medical Center were found to have significant hypophosphatemia, with phosphate levels ranging from less than 1.0 to 1.3 mg/dL (normal: 2.5-4.5 mg/dL).

In three patients, phosphate levels normalized spontaneously within hours without supplementation, suggesting redistribution of phosphate between compartments rather than true depletion. Hyperventilation, observed in four of the six patients, may have contributed by shifting phosphate into cells.

This represents a previously unrecognized electrolyte complication of CHS that could have clinical consequences if severe or prolonged.

Why it matters

Severe hypophosphatemia can cause muscle weakness, respiratory failure, seizures, and cardiac dysfunction. Recognizing this as a feature of CHS is important for emergency medicine providers who may otherwise overlook phosphate testing in these patients or attribute symptoms to the hyperemesis itself.

The numbers in context

6 male patients. Phosphate range: <1.0-1.3 mg/dL (normal 2.5-4.5). 3 patients normalized spontaneously within hours. Hyperventilation present in 4 of 6 patients. Study period: 2011-2014.

How the study worked

Retrospective case series of six male patients treated for cannabinoid hyperemesis syndrome at the San Diego VA Medical Center between 2011 and 2014. Phosphate levels and clinical features were reviewed from medical records.

What this study cannot tell us

Very small case series (6 patients, all male, all from a VA). The mechanism (hyperventilation-induced redistribution) is proposed but not definitively proven. Other causes of hypophosphatemia (vomiting, poor intake) may contribute. The cases may not represent the typical CHS population.

How to read the evidence

Small case series of 6 patients from a single center. Identifies a novel clinical finding but cannot establish prevalence or definitive mechanism.

When this study was published

Published in 2017. The electrolyte complications of CHS continue to be characterized.

The bigger picture

CHS is increasingly recognized but its full clinical picture continues to expand. Electrolyte derangements add another dimension to what was initially described as simply a vomiting syndrome. Clinicians managing CHS need to check electrolytes including phosphate, not just treat the nausea.

Questions still open

How common is hypophosphatemia in CHS? Do other electrolyte abnormalities frequently accompany CHS? Should routine electrolyte panels be recommended for all CHS presentations?

Common questions

What is hypophosphatemia and why is it dangerous?

Hypophosphatemia is abnormally low blood phosphate. Phosphate is essential for cellular energy production, muscle function, and oxygen delivery. Severe cases can cause muscle weakness, respiratory failure, seizures, and heart rhythm problems.

Why did the phosphate levels fix themselves?

In three patients, phosphate normalized within hours without treatment. The researchers suggest hyperventilation (observed in most patients) shifted phosphate from the blood into cells, creating a temporary low reading rather than true depletion. Once breathing normalized, phosphate redistributed back.

Read the original research

Hypophosphatemia in Users of Cannabis.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 69(1), 152-155

View on PubMed ↗Publisher’s paper ↗

Citation

Cadman, Peter E. (2017). Hypophosphatemia in Users of Cannabis.. American journal of kidney diseases : the official journal of the National Kidney Foundation, 69(1), 152-155. https://doi.org/10.1053/j.ajkd.2016.06.028